[go: up one dir, main page]

NO20090541L - Prodrug av cinnamidforbindelse - Google Patents

Prodrug av cinnamidforbindelse

Info

Publication number
NO20090541L
NO20090541L NO20090541A NO20090541A NO20090541L NO 20090541 L NO20090541 L NO 20090541L NO 20090541 A NO20090541 A NO 20090541A NO 20090541 A NO20090541 A NO 20090541A NO 20090541 L NO20090541 L NO 20090541L
Authority
NO
Norway
Prior art keywords
prodrug
cinnamide compound
formula
group
cinnamide
Prior art date
Application number
NO20090541A
Other languages
English (en)
Inventor
Teiji Kimura
Koki Kawano
Noritaka Kitazawa
Nobuaki Sato
Toshihiko Kaneko
Koichi Ito
Mamoru Takaishi
Ikuo Kushida
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO20090541L publication Critical patent/NO20090541L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Cultivation Of Plants (AREA)
  • Seasonings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Beskrevet er et optimalt prodrug til en cinnamidforbindelsen representert ved formel (I). I formelen representerer Ra og Rrespektivt en Cl-6 alkylgnippe eller lignende; Xrepresenterer en metoksygmppe eller et fiuoratom; Y representerer en fosfonogmppe eller lignende; og A representerer et cyklisk laktamderivat.
NO20090541A 2006-07-28 2009-02-03 Prodrug av cinnamidforbindelse NO20090541L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82076106P 2006-07-28 2006-07-28
JP2006206007 2006-07-28
US86925906P 2006-12-08 2006-12-08
JP2006331274 2006-12-08
PCT/JP2007/064637 WO2008013213A1 (en) 2006-07-28 2007-07-26 Prodrug of cinnamide compound

Publications (1)

Publication Number Publication Date
NO20090541L true NO20090541L (no) 2009-02-03

Family

ID=38981524

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090541A NO20090541L (no) 2006-07-28 2009-02-03 Prodrug av cinnamidforbindelse

Country Status (25)

Country Link
US (1) US7737141B2 (no)
EP (1) EP2048143A4 (no)
JP (1) JPWO2008013213A1 (no)
KR (1) KR20090033910A (no)
AR (1) AR062095A1 (no)
AU (1) AU2007277729A1 (no)
CA (1) CA2658037A1 (no)
CO (1) CO6150153A2 (no)
CR (1) CR10499A (no)
EA (1) EA200970172A1 (no)
EC (1) ECSP099091A (no)
GE (1) GEP20115176B (no)
HN (1) HN2009000157A (no)
IL (1) IL196351A0 (no)
MA (1) MA30636B1 (no)
MX (1) MX2008015504A (no)
MY (1) MY144971A (no)
NO (1) NO20090541L (no)
NZ (1) NZ574102A (no)
PE (1) PE20080281A1 (no)
SA (1) SA07280403B1 (no)
SV (1) SV2009003157A (no)
TN (1) TN2009000024A1 (no)
TW (1) TW200821319A (no)
WO (1) WO2008013213A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
KR20070083781A (ko) * 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물의 비정질체
EP1953151A4 (en) * 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
KR20080076907A (ko) * 2005-11-18 2008-08-20 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 유도체의 제조 방법
AU2006317457B2 (en) * 2005-11-24 2011-09-08 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
PE20081791A1 (es) * 2007-02-28 2009-02-07 Eisai Randd Man Co Ltd Dos derivados ciclicos de oxomorfolina
KR20100016580A (ko) * 2007-05-16 2010-02-12 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 유도체의 원폿 제조 방법
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CN101815713B (zh) * 2007-08-31 2013-09-11 卫材R&D管理有限公司 多环化合物
AU2008345573B2 (en) 2007-12-20 2013-12-19 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2009080533A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
ATE535515T1 (de) 2008-01-11 2011-12-15 Hoffmann La Roche Modulatoren für amyloid beta
WO2009096349A1 (ja) * 2008-01-28 2009-08-06 Eisai R & D Management Co., Ltd. 結晶性のシンナミド化合物またはその塩
RU2010137300A (ru) 2008-02-22 2012-03-27 Ф. Хоффманн-Ля Рош Аг (Ch) Модуляторы бета-амилоида
CN102177151A (zh) 2008-10-09 2011-09-07 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
MX2011004954A (es) 2008-11-10 2011-05-30 Hoffmann La Roche Moduladores heterociclicos de gamma-secretasa.
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
JP5774694B2 (ja) * 2010-07-02 2015-09-09 バイオ−ファーム ソリューションズ カンパニー リミテッド フェニルカルバメート化合物およびこれを含む筋肉弛緩剤
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
JP5838226B2 (ja) 2011-01-13 2016-01-06 バイオ−ファーム ソリューションズ カンパニー リミテッド フェニルカルバメート誘導体の製造方法
RU2014100963A (ru) 2011-06-15 2015-07-20 Басф Се Разветвленные сложные полиэфиры с сульфонатными группами
US8901066B2 (en) 2011-06-15 2014-12-02 Basf Se Branched polyesters with sulfonate groups
EP2797881B1 (en) * 2011-12-27 2018-11-14 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
CN105164103B (zh) * 2013-03-12 2019-12-06 比皮艾思药物研发有限公司 苯基氨基甲酸酯化合物和含有其的预防或治疗记忆缺失相关疾病的组合物
JP6062077B2 (ja) 2013-03-12 2017-01-18 バイオ−ファーム ソリューションズ カンパニー リミテッド 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｐｅｄｉａｔｒｉｃｅｐｉｌｅｓｙａｎｄｅｐｉｌｅｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅｓ｝
PL3552017T3 (pl) * 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
CN110143935B (zh) * 2019-06-03 2022-09-30 华侨大学 一种2，5-二取代呋喃衍生物的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689506D1 (de) 1985-10-09 1994-02-17 Shell Int Research Neue Acrylsäureamide.
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
WO1991012237A1 (en) 1990-02-08 1991-08-22 Eisai Co., Ltd. Benzenesulfonamide derivative
JPH05194517A (ja) 1992-01-16 1993-08-03 Tanabe Seiyaku Co Ltd ６−メルカプトプリン誘導体及びその製法
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
CA2200981A1 (en) 1994-10-04 1996-04-11 Hisashi Takasugi Urea derivatives and their use as acat-inhibitors
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
CZ358598A3 (cs) 1996-05-10 1999-03-17 Icos Corporation Karbolinové deriváty
PL331338A1 (en) 1996-07-22 1999-07-05 Monsanto Co Thiosulphonamidic metaloprotease inhibitors
JP2001508767A (ja) 1996-12-02 2001-07-03 藤沢薬品工業株式会社 ５―ｈｔ拮抗作用を有するインドール―ウレア誘導体
RU2189982C2 (ru) 1997-03-31 2002-09-27 Такеда Кемикал Индастриз, Лтд. Азольные соединения, способ их получения, противогрибковая фармацевтическая композиция и способ лечения грибковой инфекции
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
ATE261730T1 (de) 1997-12-31 2004-04-15 Univ Kansas Wasserlösliche medikamentenvorstufen tertiärer amine enthaltender medikamente und verfahren zu ihrer herstellung
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
IL144781A0 (en) 1999-02-26 2002-06-30 Merck & Co Inc Novel sulfonamide compounds and uses thereof
WO2000051981A1 (en) 1999-03-04 2000-09-08 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
AU2001241128A1 (en) 2000-03-14 2001-09-24 Fujisawa Pharmaceutical Co. Ltd. Novel amide compounds
US20010051642A1 (en) 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
WO2001081312A2 (en) 2000-04-24 2001-11-01 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
MXPA03004862A (es) 2000-12-04 2005-02-14 Hoffmann La Roche Derivados de feniletenilo o feniletinilo como antagonistas del receptor de glutamato.
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
PL373484A1 (en) 2001-12-10 2005-09-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1465861B1 (en) 2001-12-20 2009-05-06 Bristol-Myers Squibb Company Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
DE10211101A1 (de) 2002-03-14 2003-09-25 Basf Ag Katalysatoren und Verfahren zur Herstellung von Aminen
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
EP1542692B1 (en) 2002-05-22 2011-01-05 Amgen Inc. Aminopyrimidine derivatives for use as vanilloid receptor ligands for the treatment of pain
CA2486869C (en) 2002-05-31 2011-09-13 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
AU2003249937A1 (en) 2002-07-12 2004-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
AU2004210711B2 (en) 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
AP2331A (en) 2003-12-22 2011-12-05 Pfizer Triazole derivatives as vasopressin antagonists.
AU2005214349B2 (en) 2004-02-12 2011-11-03 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
KR20070083781A (ko) 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물의 비정질체
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
KR20080076907A (ko) 2005-11-18 2008-08-20 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 유도체의 제조 방법
EP1953151A4 (en) 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
AU2006317457B2 (en) 2005-11-24 2011-09-08 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
MX2009012177A (es) 2007-05-07 2009-11-23 Schering Corp Moduladores de gamma-secretasa.
MX2009012163A (es) 2007-05-11 2009-12-01 Hoffmann La Roche Hetarilanilinas como moduladores para beta-amiloide.
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
US20110009392A1 (en) 2007-08-06 2011-01-13 Schering Corporation Gamma secretase modulators

Also Published As

Publication number Publication date
CR10499A (es) 2009-03-20
EP2048143A1 (en) 2009-04-15
CO6150153A2 (es) 2010-04-20
IL196351A0 (en) 2009-09-22
TN2009000024A1 (en) 2010-08-19
AU2007277729A1 (en) 2008-01-31
JPWO2008013213A1 (ja) 2009-12-17
TW200821319A (en) 2008-05-16
HN2009000157A (es) 2011-01-24
PE20080281A1 (es) 2008-05-05
SA07280403B1 (ar) 2010-12-01
MA30636B1 (fr) 2009-08-03
MY144971A (en) 2011-11-30
US7737141B2 (en) 2010-06-15
EP2048143A4 (en) 2010-11-03
ECSP099091A (es) 2009-02-27
EA200970172A1 (ru) 2009-08-28
AR062095A1 (es) 2008-10-15
NZ574102A (en) 2010-10-29
WO2008013213A1 (en) 2008-01-31
GEP20115176B (en) 2011-03-10
US20090048213A1 (en) 2009-02-19
MX2008015504A (es) 2008-12-18
KR20090033910A (ko) 2009-04-06
CA2658037A1 (en) 2008-01-31
SV2009003157A (es) 2010-01-12

Similar Documents

Publication Publication Date Title
NO20090541L (no) Prodrug av cinnamidforbindelse
NO20070368L (no) Virale polymeraseinhibitorer
NO20084583L (no) Makrosykliske kinase-inhibitorer
EA200801381A1 (ru) Производные пиримидина
NO20065578L (no) Substituerte metylaryl eller heteroarylamidforbindelser
NO20065573L (no) Orto-substituerte aryl eller heteroarylamidforbindelser
IN2014CN00532A (no)
NO20083390L (no) Piperaziner og piperidiner som mGluR5-forsterkere
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
NO20074311L (no) Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet
WO2006133147A3 (en) Organic compounds
NO20054425L (no) Heteroarylkarbamoylbenzenderivater
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
MX2010001773A (es) Metodo para preparar derivados de 5-haloalquil-4,5-dihidroisoxasol .
EP2133330A4 (en) ATROPISOMER OF A PYROLE DERIVATIVE
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
EA017861B9 (ru) Способ получения 4-оксохинолинового соединения
WO2009054439A1 (ja) Pai-1産生抑制剤
WO2008126804A1 (ja) レジスト下層膜形成組成物
NO20075904L (no) Benzimidazolforbindelser
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
NO20071012L (no) Fremgangsmate for fremstilling av D-erytro-2,2-difluor-2-deoksy-1-oksoribosederivat
ATE501103T1 (de) Organische verbindungen
MY146663A (en) Organic sulfur compound and its use for controlling harmful arthropod

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application